Compare DexCom, Inc. (DXCM) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Garmin Ltd. — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Garmin Ltd. trades at $271.28 (market cap $51.77B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays a 1.56% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Garmin Ltd. for 83 Days on average.
| DXCM | GRMN | |
|---|---|---|
Market Cap | $31.86B | $51.77B |
Volume | 3,607,070 | 961,398 |
Sector | Health | Technology |
52-Week High | $92.34 | $313.16 |
52-Week Low | $54.84 | $187.10 |
Typical Hold Time | 62 Days | 83 Days |
Enterprise Value | $31.32B | $49.28B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Garmin (GRMN) trades at $276.16, down 1.09% today, showing strong fundamentals with consistent earnings beats and robust profitability. The company maintains impressive gross margins of 60.08% and net income margins of 24.47%, supported by steady revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive developments include multiple product awards and new feature rollouts across marine, fitness, and automotive segments, though technical indicators suggest near-term bearish pressure.
Garmin presents a compelling investment case with strong financial performance and analyst consensus target of $320.25 (16% upside). However, elevated valuation ratios (P/E 28.5, P/S 6.97) and technical bearish signals warrant caution. Key risks include competitive pressures in wearable technology and potential economic sensitivity in consumer discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
